Jones Hill Capital’s Contineum Therapeutics CTNM Stock Holding History

Jones Hill Capital’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-513,053	Closed	-$6.7M	–	39
2026 Q1	$6.7M	Buy	+513,053	New	+$6.88M	1.44%	17

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jones Hill Capital's CTNM Position: Q2 2026 in Review

Jones Hill Capital sold out of Contineum Therapeutics (CTNM) in Q2 2026, closing a stake of 513,053 shares — an estimated $6.7M sold.

Jones Hill Capital first reported a position in CTNM in Q1 2026 and held it in 1 quarter. The position peaked at $6.7M in Q1 2026. 101 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Jones Hill Capital reported no remaining Contineum Therapeutics position as of Q2 2026 after selling out during the quarter.
Jones Hill Capital sold 513,053 Contineum Therapeutics shares in Q2 2026, an estimated $6.7M.
Jones Hill Capital first reported a position in Contineum Therapeutics in Q1 2026 and held it in 1 quarter.
Jones Hill Capital's Contineum Therapeutics position peaked at $6.7M in Q1 2026.
101 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Jones Hill Capital's 13F filing for Q2 2026, filed 13 Aug 2026.